CB-6, JS-016, LY3832479, LY-CoV-016, CAS: 2423948-94-9

Human

DVV00306A pdf (datasheet)

100 ug

$475.00 BUY

1.0 mg/ml, lot specific

Recombinant Human anti-SARS-CoV-2 Spike Protein Receptor Binding domain, Etesevimab (Clone CB6, JS016), is expressed in XtenCHO. The monoclonal antibody JS016, was obtained from a B lymphocyte of a COVID-19 survivor, and binds with high-affinity to the receptor-binding domain within the S1 subunit of the SARS-CoV-2 spike protein, thus blocking the binding between the virus and the cell surface receptor angiotensin-converting enzyme 2 (ACE2). The spike glycoprotein is found on the outside of the virus particle and gives coronavirus viruses their crown-like appearance. Spike glycoprotein is cleaved into the following 3 chains, Spike protein S1, Spike protein S2, Spike protein S2'. Spike protein S1 attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein. Surface glycoprotein is an important target for vaccine development, antibody therapies and diagnostic antigen-based tests.

S

P0DTC2

2423948-94-9

DVV00306

Recognizes SARS-CoV-2 Spike-RBD protein

Human

IgG1 Kappa light chain

Sterile-filtered 0.01M PBS, pH 7.4
Endotoxin: 0.01EU/ug by LAL analysis

Protein A affinity chromatography

FS , Neutralizing

Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.